Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 22.83.
Forward PE Ratio (22.83) = Close Price ($56.39) / Consensus Forward EPS ($2.47)
FORWARD PE RATIO
22.83
SECTOR MEDIAN · HEALTHCARE
20.29
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+12.55%
vs the sector median at left
Roche Holding AG
Market Cap
$359.46B
Forward PE Ratio
22.83
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 22.83 |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 19.99 |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 55.70 |
| AbbVie Inc. (ABBV)vs › | $455.87B | 18.74 |
| AstraZeneca PLC (AZN)vs › | $255.15B | 16.24 |
| Amgen Inc. (AMGN)vs › | $235.85B | 19.08 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 25.12 |
| Novo Nordisk A/S (NVO)vs › | $205.42B | N/A |
| Abbott Laboratories (ABT)vs › | $193.04B | 20.68 |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | N/A |
Trailing P/E
16.1
reported TTM EPS
Forward P/E
22.8
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.47 implies -29.2% EPS decline vs the reported trailing $3.49.
At today's $56.39 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.47 | $2.11 – $2.58 | 5 | 22.8x |
| 2027-12-31 | $2.67 | $2.34 – $2.79 | 5 | 21.1x |
| 2028-12-31 | $2.89 | $2.77 – $3.04 | 2 | 19.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute